Immune Therapy of HPV-induced Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01462838|
Recruitment Status : Completed
First Posted : October 31, 2011
Last Update Posted : June 23, 2015
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|HPV-induced Cancers||Biological: P16_37-63||Phase 1 Phase 2|
The present study is initiated to evaluate vaccination with P16_37-63 -peptide in patients with advanced HPV- and p16INK4a -positive cervical, vulvar, vaginal, penile, anal or head and neck cancer. Specifically, the present study aims at the following questions:
- Evaluation of potential toxicity of the vaccination with P16_37-63 -peptide
- Evaluation of the immune response in patients with advanced HPV- and p16INK4a-positive cervical, vulvar, vaginal, penile, anal or head and neck cancer before vaccination and after vaccination with P16_37-63.
In this context, the present study shall demonstrate whether application of P16_37-63 in a vaccination approach is associated with the induction of peptide-related toxicity. Hence, the study marks the first step towards the application of P16_37-63 in humans, as it provides information on the safety of P16_37-63 as vaccination agent for the first time. Moreover, the study shall provide initial information, whether vaccination with P16_37-63 can induce p16INK4a -specific immune responses in patients with advanced HPV- and p16INK4a -positive cervical, vulvar, vaginal, penile, anal or head and neck cancer. Thus, it shall provide information, whether P16_37-63 has the potential to elicit peptide-specific immune responses and therefore represent a suitable target for the induction of tumor antigen-specific immune responses in this population.
The present study marks an important milestone towards a potential application of P16_37-63 as therapeutic agent in the management of patients with advanced HPV- and p16INK4a -positive cervical, vulvar, vaginal, penile, anal or head and neck cancer. Long-term goal of this approach is to develop novel tools for the palliative and/or adjuvant therapy of patients with advanced advanced HPV- and p16INK4a -positive tumors.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/IIa Study of Immunization With a p16INK4a Peptide Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-associated Cancers|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||May 2015|
P16_37-63 peptide plus Montanide ISA-51 VG
100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
- Immune response [ Time Frame: every 2 weeks ]Immune response against peptide P16_37-63. A positive immune response is defined as positive DTH response against peptide P16_37-63 or a humoral (ELISA for the detection of p16-specific IgG/IgM/IgA) and/or CD8 and/or CD4 cellular (IFN gamma ELISpot for the detection of p16INK4a-specific T cells) immune response exceeding the assay specific cut-off values for a positive response against peptide P16_37-63.
- Tumor response [ Time Frame: every 8 weeks ]assessed by CT or MRI scans according to RECIST
- safety [ Time Frame: up to 8 months ]number and severity of adverse events categorized according to CTC criteria version 4.0
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed, advanced HPV-positive cervical, vulvar, vaginal, penile, anal or head and neck cancer cancers under progression, regression or with stable disease after standard therapy (and still incurable) or after refusal of standard therapy or with contraindications for standard treatment
- HPV positivity as tested by HPV genotyping from paraffin embedded tumor tissue
- Diffuse expression of p16INK4a in the tumor as analyzed by immunohistochemistry on paraffin embedded tumor tissue.
- Expected survival of at least six months.
- Full recovery from surgery, chemo therapy or radiation therapy.
- ECOG performance status 0, 1 or 2.
- The following laboratory results:
Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet count ≥ 100 x 109/L Serum bilirubin < 2mg/dL
- Male or female patients ≥ 18 years old
- Patient´s written informed consent for participation in the trial
- Prior treatment with P16_37-63 peptide
- Clinically significant heart disease (NYHA Class III or IV).
- Other serious illnesses, eg, serious infections requiring antibiotics or bleeding disorders.
- History of immunodeficiency disease or autoimmune disease.
- Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
- HBV, HCV or HIV positivity.
- Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry
- Concomitant treatment with steroids, antihistaminic drugs, or nonsteroidal anti-inflammatory drugs (unless used in low doses for prevention of an acute cardiovascular event or for pain control). Topical or inhalational steroids are permitted.
- Participation in any other clinical trial involving another investigational agent within 4 weeks.
- Pregnancy or lactation.
- Women of childbearing potential who are not using a medically acceptable means of contraception.
- Psychiatric or addictive disorders that may compromise the ability to give informed consent.
- Lack of availability of a patient for immunological and clinical follow-up assessment.
- Brain metastases (symptomatic and non-symptomatic)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01462838
|Frankfurt/Main, Germany, 60488|
|Principal Investigator:||Elke Jäger, Prof. Dr.||Krankenhaus Nordwest Frankfurt|
|Responsible Party:||Oryx GmbH & Co. KG|
|Other Study ID Numbers:||
|First Posted:||October 31, 2011 Key Record Dates|
|Last Update Posted:||June 23, 2015|
|Last Verified:||June 2015|